Comparing Rivaroxaban and Apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria

27 August 2021 (08:00 - 20:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Jelle C L Himmelreich

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

160 More presentations in this session

Presentation thumbnail

The impact of abnormal conduction zone on outcomes after catheter ablation for atrial fibrillation

Associate Professor T. Mine (Nishinomiya, JP)

Abstract Slides

Presentation thumbnail

Thromboembolic risk of movable type left atrial appendage thrombi in patients with atrial fibrillation under widespread use of anticoagulants

Doctor M. Sugitani (Nishinomiya, JP)

Abstract Slides

Presentation thumbnail

Rate and rhythm control treatment in the elderly and very elderly patients with atrial fibrillation: an observational cohort study of 1,497 patients

Mr T. Klamer (Amsterdam, NL)

Abstract Slides

Presentation thumbnail

One year outcome and analysis of peri-device leak of left atrial appendage occlusion devices

Doctor M. Mansour (Beirut, LB)

Abstract Slides

Presentation thumbnail

Risk prediction of atrial fibrillation and its complications in the community using high-sensitivity cardiac Troponin I: Results from the BiomarCaRE Consortium

Doctor C. Boerschel (Hamburg, DE)

Abstract Slides

Access the full session

Session thumbnail

Atrial fibrillation e-posters

The Event

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Session

Oral anticoagulation in subclinical atrial fibrillation

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources